Investors tell Silence Therapeutics to shush

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning. Today, we meet Pfizer’s new chief scientific officer, ponder why the stock for Silence Therapeutics dropped despite promising data, and see that pharma executives aren’t too worried about Robert F. Kennedy, Jr.

Read the rest…

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!